Insider Selling: Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Director Sells 500 Shares of Stock

Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Director Rebecca B. Robertson sold 500 shares of the firm’s stock in a transaction that occurred on Wednesday, June 9th. The stock was sold at an average price of $90.00, for a total transaction of $45,000.00. Following the completion of the transaction, the director now directly owns 2,392 shares in the company, valued at approximately $215,280. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Shares of Tandem Diabetes Care stock traded up $3.39 on Thursday, hitting $91.35. 486,166 shares of the company traded hands, compared to its average volume of 733,471. The firm has a market cap of $5.72 billion, a PE ratio of -191.22 and a beta of 0.19. The company has a quick ratio of 5.75, a current ratio of 6.40 and a debt-to-equity ratio of 0.89. Tandem Diabetes Care, Inc. has a 52 week low of $76.19 and a 52 week high of $123.74. The company’s 50-day moving average price is $87.31.

Tandem Diabetes Care (NASDAQ:TNDM) last released its quarterly earnings data on Wednesday, May 5th. The medical device company reported ($0.08) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.16) by $0.08. The firm had revenue of $141.04 million for the quarter, compared to analysts’ expectations of $122.66 million. Tandem Diabetes Care had a negative net margin of 4.53% and a negative return on equity of 1.12%. As a group, research analysts anticipate that Tandem Diabetes Care, Inc. will post 0.06 earnings per share for the current year.

Several institutional investors have recently added to or reduced their stakes in the company. US Bancorp DE raised its position in shares of Tandem Diabetes Care by 16.4% during the fourth quarter. US Bancorp DE now owns 795 shares of the medical device company’s stock valued at $76,000 after buying an additional 112 shares during the last quarter. Thoroughbred Financial Services LLC raised its position in shares of Tandem Diabetes Care by 6.8% during the first quarter. Thoroughbred Financial Services LLC now owns 2,433 shares of the medical device company’s stock valued at $214,000 after buying an additional 155 shares during the last quarter. Sigma Planning Corp raised its position in shares of Tandem Diabetes Care by 3.9% during the first quarter. Sigma Planning Corp now owns 4,141 shares of the medical device company’s stock valued at $365,000 after buying an additional 155 shares during the last quarter. Xponance Inc. increased its position in Tandem Diabetes Care by 2.9% in the first quarter. Xponance Inc. now owns 5,668 shares of the medical device company’s stock worth $500,000 after purchasing an additional 161 shares during the last quarter. Finally, Banque Cantonale Vaudoise increased its position in Tandem Diabetes Care by 5.9% in the fourth quarter. Banque Cantonale Vaudoise now owns 2,929 shares of the medical device company’s stock worth $281,000 after purchasing an additional 164 shares during the last quarter. Hedge funds and other institutional investors own 91.46% of the company’s stock.

A number of equities analysts recently issued reports on TNDM shares. Lake Street Capital raised their price objective on shares of Tandem Diabetes Care from $137.00 to $150.00 and gave the stock a “buy” rating in a report on Thursday, February 25th. Zacks Investment Research downgraded shares of Tandem Diabetes Care from a “buy” rating to a “hold” rating and set a $101.00 price objective on the stock. in a report on Monday, March 1st. Barclays started coverage on shares of Tandem Diabetes Care in a report on Monday, May 24th. They issued an “underweight” rating and a $90.00 price objective on the stock. Oppenheimer raised their price objective on shares of Tandem Diabetes Care from $130.00 to $135.00 in a report on Thursday, May 6th. Finally, SVB Leerink lifted their price target on shares of Tandem Diabetes Care from $95.00 to $102.00 and gave the company a “market perform” rating in a report on Thursday, May 6th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and nine have assigned a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus price target of $117.50.

About Tandem Diabetes Care

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes various products for people with insulin-dependent diabetes in the United States. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform that comprises t:slim X2 pump, its 300-unit disposable insulin cartridge, and an infusion set.

Recommended Story: Overbought

Insider Buying and Selling by Quarter for Tandem Diabetes Care (NASDAQ:TNDM)

Receive News & Ratings for Tandem Diabetes Care Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tandem Diabetes Care and related companies with MarketBeat.com's FREE daily email newsletter.